Abstract
The position of the dose-response curve for steroid-regulated gene expression determines how much variation in response will accompany the normal physiological changes in circulating steroid. Over the last several years, it has become clear that the concentration of steroid hormone required for half-maximal induction or repression by a given receptor-steroid complex, which is normally called the EC50, is not constant for all responsive genes. Thus, the position of the dose-response curve can change so that a single concentration of steroid produces very different percentages of maximal activity. This, in turn, allows for the differential expression of genes by a common steroid hormone concentration during development, differentiation, and homeostasis. Here we review the variety of factors that influence the EC50 and position of the dose-response curve for steroid hormone receptors, discuss what is known about the mechanisms, and highlight promising areas for future research.
Keywords: receptor-steroid interactions, dissociation constant, Corepressors, Michaelis-Menton kinetics, Ubc9, Chaperone Proteins
Current Topics in Medicinal Chemistry
Title: How Much is Enough? Modulation of Dose-Response Curve for Steroid Receptor-Regulated Gene Expression by Changing Concentrations of Transcription Factor
Volume: 6 Issue: 3
Author(s): S. S. Simons Jr.
Affiliation:
Keywords: receptor-steroid interactions, dissociation constant, Corepressors, Michaelis-Menton kinetics, Ubc9, Chaperone Proteins
Abstract: The position of the dose-response curve for steroid-regulated gene expression determines how much variation in response will accompany the normal physiological changes in circulating steroid. Over the last several years, it has become clear that the concentration of steroid hormone required for half-maximal induction or repression by a given receptor-steroid complex, which is normally called the EC50, is not constant for all responsive genes. Thus, the position of the dose-response curve can change so that a single concentration of steroid produces very different percentages of maximal activity. This, in turn, allows for the differential expression of genes by a common steroid hormone concentration during development, differentiation, and homeostasis. Here we review the variety of factors that influence the EC50 and position of the dose-response curve for steroid hormone receptors, discuss what is known about the mechanisms, and highlight promising areas for future research.
Export Options
About this article
Cite this article as:
Simons Jr. S. S., How Much is Enough? Modulation of Dose-Response Curve for Steroid Receptor-Regulated Gene Expression by Changing Concentrations of Transcription Factor, Current Topics in Medicinal Chemistry 2006; 6 (3) . https://dx.doi.org/10.2174/156802606776173465
DOI https://dx.doi.org/10.2174/156802606776173465 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery to Macrophages in Parasitic Infections
Current Drug Delivery The Role of Anionic Polysaccharides in the Preparation of Nanomedicines with Anticancer Applications
Current Pharmaceutical Design Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation
Current Medicinal Chemistry Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design